BML Inc
BML, Inc. provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, aller… Read more
BML Inc (BMZ) - Net Assets
Latest net assets as of September 2025: €130.01 Billion EUR
Based on the latest financial reports, BML Inc (BMZ) has net assets worth €130.01 Billion EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€173.81 Billion) and total liabilities (€43.81 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €130.01 Billion |
| % of Total Assets | 74.8% |
| Annual Growth Rate | 8.31% |
| 5-Year Change | 43.65% |
| 10-Year Change | N/A |
| Growth Volatility | 8.96 |
BML Inc - Net Assets Trend (2016–2025)
This chart illustrates how BML Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BML Inc (2016–2025)
The table below shows the annual net assets of BML Inc from 2016 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €133.77 Billion | +2.79% |
| 2024-03-31 | €130.14 Billion | +2.67% |
| 2023-03-31 | €126.75 Billion | +4.16% |
| 2022-03-31 | €121.68 Billion | +30.67% |
| 2021-03-31 | €93.12 Billion | +15.79% |
| 2020-03-31 | €80.42 Billion | -0.87% |
| 2019-03-31 | €81.13 Billion | +6.44% |
| 2018-03-31 | €76.22 Billion | +7.89% |
| 2017-03-31 | €70.65 Billion | +8.35% |
| 2016-03-31 | €65.20 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to BML Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 142.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €122.48 Billion | 94.66% |
| Other Components | €6.92 Billion | 5.34% |
| Total Equity | €129.40 Billion | 100.00% |
BML Inc Competitors by Market Cap
The table below lists competitors of BML Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
APARTM.INV. MGMT A DL-01
F:AIV
|
$462.36 Million |
|
Metsa Board Corp. Series B
LSE:0O7A
|
$462.37 Million |
|
ACNB Corporation
NASDAQ:ACNB
|
$462.57 Million |
|
Cantor Equity Partners IV, Inc. Class A Ordinary Shares
NASDAQ:CEPF
|
$462.60 Million |
|
CHINA OVERSEAS (SWL.SG)
STU:SWL
|
$461.97 Million |
|
Aegean Airlines S.A
PINK:AGZNF
|
$461.90 Million |
|
Rami Levi Chain Stores Hashikma Marketing 2006 Ltd
PINK:RLEVF
|
$461.86 Million |
|
Esso Thailand PCL
STU:JAV
|
$461.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BML Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 125,864,000,000 to 129,400,000,000, a change of 3,536,000,000 (2.8%).
- Net income of 6,263,000,000 contributed positively to equity growth.
- Dividend payments of 3,509,000,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €6.26 Billion | +4.84% |
| Dividends Paid | €3.51 Billion | -2.71% |
| Other Changes | €782.00 Million | +0.6% |
| Total Change | €- | 2.81% |
Book Value vs Market Value Analysis
This analysis compares BML Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | €1584.90 | €22.00 | x |
| 2018-03-31 | €1705.07 | €22.00 | x |
| 2019-03-31 | €1810.94 | €22.00 | x |
| 2020-03-31 | €1874.79 | €22.00 | x |
| 2021-03-31 | €2175.31 | €22.00 | x |
| 2022-03-31 | €2910.10 | €22.00 | x |
| 2023-03-31 | €3139.16 | €22.00 | x |
| 2024-03-31 | €3228.60 | €22.00 | x |
| 2025-03-31 | €3317.39 | €22.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BML Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.37%
- • Asset Turnover: 0.81x
- • Equity Multiplier: 1.37x
- Recent ROE (4.84%) is below the historical average (10.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 8.71% | 4.98% | 1.10x | 1.60x | €-801.20 Million |
| 2017 | 8.83% | 5.35% | 1.07x | 1.55x | €-786.00 Million |
| 2018 | 8.25% | 5.28% | 1.04x | 1.51x | €-1.27 Billion |
| 2019 | 8.62% | 5.67% | 1.01x | 1.50x | €-1.07 Billion |
| 2020 | 8.37% | 5.28% | 1.04x | 1.53x | €-1.24 Billion |
| 2021 | 15.51% | 9.89% | 1.00x | 1.57x | €4.87 Billion |
| 2022 | 29.04% | 18.13% | 1.04x | 1.54x | €22.12 Billion |
| 2023 | 12.72% | 9.77% | 0.94x | 1.38x | €3.33 Billion |
| 2024 | 4.79% | 4.37% | 0.81x | 1.36x | €-6.55 Billion |
| 2025 | 4.84% | 4.37% | 0.81x | 1.37x | €-6.68 Billion |
Industry Comparison
This section compares BML Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $744,954,496
- Average return on equity (ROE) among peers: -39.32%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BML Inc (BMZ) | €130.01 Billion | 8.71% | 0.34x | $462.01 Million |
| Spermosens AB (publ) (9R5) | $23.64 Million | -27.17% | 0.09x | $517.28K |
| Genomic Vision Société Anonyme (G09) | $3.07 Million | -162.85% | 1.21x | $711.54K |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.43 Billion |
| Adicon Holdings Limited (K0U) | $1.77 Billion | 2.65% | 1.64x | $138.53 Million |
| WuXi XDC Cayman Inc. (L74) | $1.48 Billion | 10.52% | 0.69x | $2.11 Billion |
| NanoRepro AG (NN6) | $57.61 Million | 51.59% | 0.37x | $16.84 Million |
| PERRIGO (PGO) | $24.67 Million | -167.93% | 0.99x | $6.37K |